The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•12 May 2026•

1 min read

Google-backed Isomorphic Labs Raises $2.1 Billion for AI Drug Discovery

Key Facts

1AI-driven drug discovery company Isomorphic Labs raised $2.1 billion in its latest funding round.

2The funding round for the Google-backed company was led by existing investor Thrive Capital.

AI-driven drug discovery company Isomorphic Labs raised $2.1 billion in its latest funding round. The funding round for the Google-backed company was led by existing investor Thrive Capital. This capital injection is intended to scale the company's capabilities in using artificial intelligence to accelerate and improve the process of drug discovery.

This move comes as the AI-biotech sector experiences rapid growth, with big tech firms deepening their footprint in healthcare. Per market data, this funding positions Isomorphic Labs strongly against peers like Recursion Pharmaceuticals and Schrödinger, which recently reported earnings highlighting increased investment in digital R&D (per Q1 search data).

Investors are now watching how effectively the company converts this massive capital into tangible laboratory results. Looking at the economic calendar, traders are awaiting the Initial Jobless Claims in the US on May 7, 2026, which may influence broader risk appetite for the technology and growth sectors.